Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.2460/javma.2004.225.1533 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Detection of multiple myositis-specific antibodies: prevalence and clinical significance.
Lab Med
January 2025
Immunology Department, Habib Bourguiba University Hospital, University of Sfax, Sfax, Tunisia.
Background: The multipositivity of myositis-specific antibodies (MSAs) is uncommon. Our study aimed to assess the prevalence and the clinical relevance of multiple positive MSAs in routine practice.
Methods: A 10 year single-center retrospective study (2015-2024) was conducted reviewing all samples analyzed with the Dot Myositis EUROLINE (Euroimmun Germany).
Rheumatologic complications of CAR-T Cell therapy. Experience of a single center.
Semin Arthritis Rheum
December 2024
Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain; Department of Immunology, CDB, Hospital Clínic, Barcelona, Spain.
Introduction: Chimeric Antigen Receptor T-cell (CAR-T) therapy has emerged as a promising treatment for hematological malignancies. However, its association with immune-related complications such as rheumatic complications, is not well defined.
Methods: We conducted a retrospective study to analyze rheumatic complications in 310 patients treated with CAR-T therapy at a single center from January 2020 to May 2024.
Spontaneously regressing mass-like soft tissue involvement in a child with chronic non-bacterial osteomyelitis: case-based review.
Rheumatol Int
January 2025
Department of Pediatric Rheumatology, Istanbul Medeniyet University, Istanbul, Turkey.
Chronic non-bacterial osteomyelitis (CNO) is an inflammatory bone disease, usually diagnosed in childhood. It is characterized by the presence of multifocal or unifocal osteolytic lesions that can cause bone pain and soft tissue swelling. CNO is known to have soft tissue involvement.
View Article and Find Full Text PDFMyositis associated with pembrolizumab presenting with myastheniform symptoms: two case reports.
Anticancer Drugs
February 2025
Department of Neurology, Bezmialem Vakif University, Medical Faculty, Istanbul, Turkey.
Immune checkpoint inhibitors (ICIs), such as pembrolizumab, have revolutionized cancer treatment by enhancing the immune system's response to malignancies. However, these therapies are associated with immune-related adverse events (irAEs), including neuromuscular complications such as myasthenia gravis, myositis, and myocarditis. We describe two male patients, aged 67 and 68, with small cell and non-small cell lung cancers, who developed progressive neuromuscular symptoms, including ptosis, diplopia, and generalized weakness, after receiving pembrolizumab.
View Article and Find Full Text PDFFirst report of iron-overload myopathy due to secondary hemochromatosis in a dog.
J Vet Sci
December 2024
Department of Veterinary Pathology, College of Veterinary Medicine, Kyungpook National University, Daegu 41566, Korea.
Importance: Hemochromatosis is rare in domestic animals, and iron-induced myopathy has not been reported in veterinary medicine. This case is the first report of iron-overload myopathy owing to hemochromatosis in a dog.
Case Presentation: A 9-year-old spayed female Donggyeong dog presented with severe forelimb lameness.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!